Recent developments dealt with novel combinations of conventional anti-cancer drugs together with biologicals or small compounds specifically targeting certain cancer cell pathways (TKs, EGF, ras/raf, PI3K-Akt, etc.). This evidence concerns the gene CDC42 and cancer.